Early start of opicapone in Parkinson's disease: evidence from a pooled analysis of phase 3 trials for sustained benefit in patients with recent onset of motor fluctuations.

ABSTRACT:

Background

Levodopa is the mainstay of Parkinson's disease (PD) therapy, but its long-term use is often complicated by the development of motor fluctuations. While COMT inhibitors, such as opicapone, are routinely used for managing motor fluctuations, recent evidence has suggested that earlier vs. later intervention, at onset of motor fluctuations, may provide greater benefits. However, the longer-term impact of earlier intervention has not been well studied.

Methods

This pooled subgroup analysis included data from randomized, 14-15 week, double-blind, placebo-controlled trials of opicapone and their 1-year open-label extensions. Exploratory analyses included all participants who were randomized to placebo or opicapone 50 mg, who continued opicapone into the open-label exten

SUBMITTER: Ferreira JJ 

PROVIDER: S-EPMC12745269 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature